Ganguly, Aniruddha
Frank, David
Kumar, Nagi
Cheng, Yung-Chi
Chu, Edward
Funding for this research was provided by:
National Institutes of Health (R01-CA160979)
National Cancer Institute (P01CA154295-01)
National Center for Complementary and Alternative Medicine (P30CA147904)
Article History
First Online: 5 March 2019
Compliance with Ethical Standards
:
: Aniruddha Ganguly declares that he has no conflict of interest.David Frank has received research funding from Gilead and Cstem; has received compensation from Kymera for service as a consultant; has a patent issued, licensed, and receives royalties for STAT Modulators; and has a patent pending for targeting the transcription factor NF-kB with harmine.Nagi Kumar declares that she has no conflict of interest.Yung-Chi Cheng is a fellow of the National Foundation for Cancer that partially supported PHY906 studies. He is a co-founder of Yiviva with the Yale University to further develop PHY906 (now known as Yiviva 906) for the treatment of various human cancers and other GI disorders.Edward Chu is a member of the scientific advisory board of Yiviva.
: All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).